Shuanghuang Kushen Powder Veterinary Grade API is a multicomponent botanical active substance used as a starting material for downstream dosage forms, including sterile injectables, tablets, capsules, soluble oral powders, medicated premixes, and granules. The powder is hygroscopic, thermally labile, and prone to particle-size segregation; therefore, each application track specified below is defined by its water activity limit, shear history, and terminal processing temperature rather than by a single universal addition ratio. Incoming lots should be controlled for baicalin and matrine/oxymatrine marker content, loss on drying, bulk density, tap density, particle size distribution, total aerobic microbial count, combined yeast and mold count, bacterial endotoxin where injectable use is intended, and residual solvent profile under VICH GL18(R2). Because published data for this specific API configuration are limited, numerical ranges in the following scenarios represent industrial screening windows for botanical extract powders with comparable hygroscopicity and marker class; they are process design ranges, not registered release limits. Confirm every value against the target market dossier before batch release.

Sterile injectable production lines handling this API encounter a distinct set of constraints arising from the botanical matrix, which contains polyphenolic fractions and polysaccharide-like material capable of fouling sterilizing-grade membranes and destabilizing sterile filtration. A production-scale 500 L jacketed stainless steel compounding vessel equipped with a bottom-mounted high-shear mixer is typically charged with Water for Injection at 45±5°C, and the API is introduced at 2.0–5.0% w/v based on the sterile intermediate volume. The final injectable concentration is subsequently adjusted by marker assay to 10.0–30.0 mg/mL total solids, because direct addition to final concentration without pre-dissolution leads to macroscopic precipitation and filter blinding. pH is corrected to 6.8–7.2 with 0.1 M sodium hydroxide or hydrochloric acid before bioburden sampling. The solution or finely dispersed suspension is pre-filtered through 0.45 µm PVDF cartridges and then through 0.22 µm PVDF sterilizing-grade filters. Differential pressure across the final filter should remain below 1.0 bar at 20–25°C; if the differential pressure exceeds 1.5 bar, the batch must be held for filter integrity testing and possible re-filtration. Terminal sterilization at 121°C for 15 min is not recommended without forced degradation data demonstrating marker recovery above acceptance limits; aseptic filtration is preferred to preserve the alkaloid and flavonoid markers.

The aseptic process must meet ISO 14644-1:2015 Class B filling-room requirements, EU GMP Annex 1 cleanroom behavior, and compendial quality attributes described in the Chinese Veterinary Pharmacopoeia (2020 Edition) monograph for Shuanghuang Kushen San where applicable. In-process control follows 21 CFR 211.110 for microbial bioburden, pH, temperature, and filter differential pressure. Injectable-grade API lots should have bacterial endotoxin levels below 0.50 EU/mg and bioburden below 10 CFU/100 mL before sterile filtration. Terminal finished product types include single-dose 10 mL and 100 mL vials, ampoules, and lyophilized vials where reconstitution stability has been validated. A documented operational boundary is that injectable batches should not proceed when the API lot water activity exceeds 0.45, because moisture accelerates browning reactions and increases filter-blocking aggregate formation.

Why Does Tablet Hardness Drift in Low-Moisture Granulation Batches?

Tablet compression of Shuanghuang Kushen Powder exposes the interaction between residual moisture, granule porosity, and compression force. The API is blended at 3.0–12.0% w/w of the tablet core mass for standard tablets, while large-animal boluses may require higher loadings only after content uniformity risk is assessed against USP Chapter 905. The addition ratio is not fixed by dose alone; it is bounded by the marker assay of the incoming lot and the need to maintain a compressible excipient matrix. A high-shear granulator with impeller speed 150–250 rpm and chopper speed 1200–1800 rpm is used to wet-granulate the blend with 2.0–4.0% w/w povidone K30 solution. The wet mass is dried in a fluid-bed dryer at inlet temperature 55–65°C until loss on drying is 3.0–5.0%; drying below this range produces friable tablets, while drying above it increases sticking and picking because hygroscopic botanical fractions soften under compression. Milling through a 0.8 mm screen and lubrication with 0.5–1.0% w/w magnesium stearate for 3–5 min is followed by compression on a rotary press at 8–18 kN and turret speed 30–60 rpm. Hardness is maintained at 60–100 N for standard tablets and friability at ≤1.0%; capping or lamination at the tablet crown is observed when granule Carr index rises above 25% or Hausner ratio exceeds 1.40. Dissolution monitoring under USP Chapter 711 apparatus II at 50 rpm in 900 mL purified water should be used to detect process drift in marker release. Compliance for tablet intermediates is anchored to 21 CFR 211.110 and the Chinese Veterinary Pharmacopoeia (2020 Edition) monograph; pharmacopoeial uniformity of dosage units applies where label claims are made. Terminal product types include 200 mg and 500 mg tablets, and 1 g boluses for target veterinary species. When relative humidity in the compression suite exceeds 60% RH, pre-conditioning of the granulation in sealed bins and immediate compression after blending are required because the API absorbs moisture rapidly and shifts tablet weight and hardness.

Metered drinking-water medication in broiler and layer houses reduces labor cost but places solubility, pH, water hardness, and dosing-pump compatibility pressure on the formulation. The most common downstream route is a concentrated soluble powder containing 20.0–50.0% w/w API, diluted at the farm to 0.5–1.0 g/L in drinking water. Regulatory compliance for this dosage form requires stability data under VICH GL11(R) and in-process control under 21 CFR 211.110; where the product is exported as a water-soluble powder for veterinary use, EU Regulation 2019/6 and national registration dossiers may apply. The production process is based on high-shear mixing of the API with a water-soluble carrier such as dextrose or lactose, passing the blend through a 0.5 mm sifter, and packaging into moisture-barrier foil sachets. A 2.0–5.0% stock solution is prepared on farm using a proportioner or venturi dosing pump; the final drinking water pH should remain between 5.5–7.5. Water quality is the main operational boundary: hard water above 400 mg/L CaCO3 can destabilize polyphenolic fractions and produce precipitate that clogs nipple drinkers, and free chlorine above 2.0 mg/L can degrade antioxidant markers. Formulators sometimes add disodium EDTA at 0.5–1.0% w/w to chelate divalent cations where field water analysis indicates high hardness. Terminal product types include 500 g, 1 kg sachets, and 5 kg pails for poultry and swine drinking water lines. Published data for this specific formulation under varying field water matrices is limited, so a site-specific reconstitution test is considered mandatory before commissioning a new production batch.

When the Powder Is Diluted into a Medicated Premix for Pelleted Rations

This application track is selected when the API is intended for feedmill integration rather than farm-level dosing. The addition ratio in the intermediate premix is 5.0–20.0% w/w, with a final complete-feed inclusion of 500–1000 g/tonne depending on the target species and regulatory claim. Compliance is anchored to feed-safety systems such as GMP+ B1, EU Regulation 2019/6 for veterinary medicinal products in medicated feed, and 21 CFR 225 for US medicated feed applications. A stepwise dilution protocol is required because direct addition of the API into a ribbon mixer creates concentration hot spots. The first step blends the API with rice bran or corncob grit at 0.2–0.8 mm particle size in a paddle mixer running at 25–35 rpm for 10–15 min; the resultant intermediate is then dispersed into the final feed. Conditioning before pelleting at 70–85°C for 30–60 s is the principal thermal risk. Where pellet-mill die temperature cannot be reduced, post-pelleting re-blending of the heat-labile marker fraction should be evaluated, because botanical alkaloid markers may show measurable loss at the upper end of this temperature window. Terminal product types include 25 kg premix bags and pelleted complete feed. The operational boundary is that post-pelleting addition is necessary when marker recovery in pilot trials falls below the registered label claim after conditioning.

Capsule filling with this botanical API is controlled primarily by blend flow and moisture. A 10.0–25.0% w/w API addition is combined with pregelatinized starch and 0.5% w/w colloidal silicon dioxide, filled at 250–400 mg total weight into size 1–2 capsules for companion animals under USP Chapter 905 uniformity and 21 CFR 211.110 in-process control. Terminal product types are limited to capsule strengths that pass fill-weight and content-uniformity validation; no additional process step is required beyond sieving and moisture control to ≤5.0% loss on drying.

Oral Granule Granulation and Moisture Control Limits

Oral granules for weanling piglet dosing require a fluid-bed top-spray granulation process that balances agglomerate growth against the API's thermal sensitivity. The API is added at 15.0–30.0% w/w of the dry granule solids, with a final oral dose of 1.0–2.0 g/animal/day administered as a drench or top-dress. The binder solution is maltodextrin at 5.0–8.0% w/w solids; the fluid-bed inlet temperature is maintained at 50–60°C, product temperature at 35–42°C, and outlet air humidity below 10 g/kg. Drying is terminated at 3.0–4.0% loss on drying, and the granulate is passed through 0.5–1.5 mm sieves to remove oversized agglomerates. VICH GL11(R) stability and the Chinese Veterinary Pharmacopoeia (2020 Edition) monograph apply; in-process testing follows 21 CFR 211.110 and USP Chapter 905 where unit-dose uniformity is claimed. Terminal product types include 100 g and 500 g granule jars with polyester-aluminum-polyethylene seals. Batch records should include a pre-drying step when the API lot water activity exceeds 0.45, because inlet-air humidity and agglomerate size both shift in humid production suites above 60% RH.